Neutralizing antibodies from early cases of SARS-CoV-2 infection offer cross-protection against the SARS-CoV-2 D614G variant.
C. Y.-P. Lee, S. N. Amrun, R. S.-L. Chee, Y. S. Goh, T. M. Mak, S. Octavia, N. Yeo, Z. W. Chang, M. Z. Tay, A. Torres, G. Carissimo, C. M. Poh, S.-W. Fong, B. Wang, S. Lee, , L. F. P. Ng
This study shows that antibodies from early SARS-CoV-2 infections neutralize both the original and D614G variants, though neutralizing capacity decreases over time.
bioRxiv · Oct 8, 2020 · PreprintImmunology